Literature DB >> 1674868

Mechanisms involved in stimulation of insulin secretion by the hypoglycaemic alpha-adrenergic antagonist, DG-5128.

S L Chan1, M R Stillings, N G Morgan.   

Abstract

The selective alpha 2-antagonist DG-5128 provoked a dose-dependent stimulation of insulin release from isolated rat islets. DG-5128 was only weakly effective as an antagonist of noradrenaline-induced inhibition of insulin secretion but, surprisingly, was able to reverse the suppression of secretion and increase in 86Rb efflux from preloaded islets, mediated by diazoxide. These effects were not reproduced with more effective alpha-antagonists, suggesting that stimulation of insulin secretion by DG-5128 is independent of alpha-receptor blockade.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1674868     DOI： 10.1016/0006-291x(91)90463-h

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  4 in total

1.  Imidazoline antagonists of alpha 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic beta-cells.

Authors:  J C Jonas; T D Plant; J C Henquin
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

2.  Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.

Authors:  C A Brown; A C Loweth; S A Smith; N G Morgan
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

3.  The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.

Authors:  S L Chan; C A Brown; K E Scarpello; N G Morgan
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

4.  Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.

Authors:  C A Brown; S L Chan; M R Stillings; S A Smith; N G Morgan
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.